George Buchlis

Spark Therapeutics (United States) — United States

Medicine · Health Sciences

13h-index1.1kcitations39works18.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(16), Immunotherapy and Immune Responses(14), Virus-based gene therapy research(14), Viral Infectious Diseases and Gene Expression in Insects(7), Monoclonal and Polyclonal Antibodies Research(6)

Publications39 total

Validation of a quantitative cell-based relative potency assay for LUXTURNA
Molecular Therapy — Methods & Clinical Development·2025Open Access
Detection of Humoral Response to Transgene Protein and Gene Editing Reagents
2024· 1 citedOpen Access
High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury
Molecular Therapy·2024· 55 citedOpen Access
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
The AAPS Journal·2023· 36 citedOpen Access
Data from Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy
2023Open Access
Supplementary Figure 1 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Figure 2 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Figure Legend 1 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Table 1 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Data from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Data from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Figure Legend 1 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Table 1 from Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy
2023Open Access
Supplementary Figure Legend 2 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Figure 2 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Table 1 from Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy
2023Open Access
Supplementary Table 1 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Figure Legend 2 from CCL2 Blockade Augments Cancer Immunotherapy
2023Open Access
Supplementary Figure 1 from Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy
2023Open Access
Data from Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Veena Kapoor(21), Guanjun Cheng(21), Linda A. Snyder(15), Sunil Singhal(14), Liang‐Chuan S. Wang(14), Zvi G. Fridlender(14), M. Cecilia Crisanti(13), Daniel F. Heitjan(13), Steven M. Albelda(11), Steven Μ. Albelda(10), Katherine A. High(9), Zvi G. Fridlender(7), Hung Kam Cheung(7), Xiamei Zhang(7), Michael J. Corbley(7), Larry R. Kaiser(7), Leona Ling(7), Daniel J. Hui(6), Jing Sun(6), Jing Sun(6)